Effect of 5-Alpha reductase inhibitors on magnetic resonance imaging and prostate cancer detection
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Morote, Juan
- dc.contributor.author Picola, Natàlia
- dc.contributor.author Muñoz-Rodríguez, Jesús
- dc.contributor.author Paesano, Nahuel
- dc.contributor.author Ruiz Plazas, Xavier
- dc.contributor.author Muñoz-Rivero, Marta V.
- dc.contributor.author Celma, Anna
- dc.contributor.author García de Manuel, Gemma
- dc.contributor.author Miró, Berta
- dc.contributor.author Servian, Pol
- dc.contributor.author Abascal-Junquera, José María
- dc.date.accessioned 2024-10-01T06:32:38Z
- dc.date.available 2024-10-01T06:32:38Z
- dc.date.issued 2024
- dc.description.abstract Concerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection. Our objective is to analyze the effect of 5-ARI on the prostate imaging-reporting and data system (PI-RADS) distribution and csPCa and insignificant PCa (iPCa) detection. Among 2212 men with serum prostate-specific antigen levels of >3.0 ng/mL and/or suspicious digital rectal examinations who underwent mpMRI and targeted and/or systematic biopsies, 120 individuals exposed to 5-ARI treatment for over a year were identified. CsPCa was defined when the grade group (GG) was >2. The overall csPCa and iPCa detection rates were 44.6% and 18.8%, respectively. Since logistic regression revealed independent predictors of PCa, a randomized matched group of 236 individuals was selected for analysis. The PI-RADS distribution was comparable with 5-ARI exposure (p 0.685). The CsPCa detection rates in 5-ARI-naïve men and 5-ARI-exposed men were 52.6% and 47.4%, respectively (p 0.596). IPCa was detected in 37.6 and 62.5%, respectively (p 0.089). The tumor GG distribution based on 5-ARI exposure was similar (p 0.149) to the rates of csPCa and iPCa across the PI-RADS categories. We conclude that exposure to 5-ARI in suspected PCa men did not change the PI-RADS distribution and the csPCa and iPCa detection rates.
- dc.format.mimetype application/pdf
- dc.identifier.citation Morote J, Picola N, Muñoz-Rodriguez J, Paesano N, Ruiz-Plazas X, Muñoz-Rivero MV, et al. Effect of 5-Alpha reductase inhibitors on magnetic resonance imaging and prostate cancer detection. Biomolecules. 2024 Feb 5;14(2):193. DOI: 10.3390/biom14020193
- dc.identifier.doi http://dx.doi.org/10.3390/biom14020193
- dc.identifier.issn 2218-273X
- dc.identifier.uri http://hdl.handle.net/10230/61282
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Biomolecules. 2024 Feb 5;14(2):193
- dc.rights © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword 5-alpha reductase inhibitors
- dc.subject.keyword Biopsy
- dc.subject.keyword Dutasteride
- dc.subject.keyword Finasteride
- dc.subject.keyword Magnetic resonance imaging
- dc.subject.keyword Prostate cancer
- dc.subject.keyword Screening
- dc.title Effect of 5-Alpha reductase inhibitors on magnetic resonance imaging and prostate cancer detection
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion